PRESS RELEASE published on 07/15/2024 at 09:30, 1 year 11 months ago Andera Partners’ portfolio company Amolyt Pharma completes acquisition by AstraZeneca Andera Partners' portfolio company Amolyt Pharma has been acquired by AstraZeneca for $1.05 billion, enhancing AstraZeneca's Rare Disease late-stage pipeline and bone metabolism franchise Acquisition Biopharmaceutical AstraZeneca Amolyt Pharma Andera Partners
BRIEF published on 07/09/2024 at 08:15, 2 years ago Andera Partners codirige la série A de 63 millions d'euros pour la biotechnologie SciRhom Produits Biopharmaceutiques Maladies Auto-immunes Financement De Série A Partenaires Andera SciRhom
BRIEF published on 07/09/2024 at 08:15, 2 years ago Andera Partners Co-Leads €63 Million Series A for Biotech SciRhom Series A Financing Biopharmaceuticals Andera Partners Autoimmune Disorders SciRhom
PRESS RELEASE published on 07/09/2024 at 08:10, 2 years ago Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom to advance novel iRhom2 antibody therapy towards clinical proof-of-concept Andera Partners SciRhom Autoimmune Biotech Series A Round IRhom2 Antibody
BRIEF published on 03/14/2024 at 11:15, 2 years 3 months ago Tubulis, la société de portefeuille d'Andera Partners, obtient un financement de série B2 de 128 millions d'euros Essais Cliniques Tubulis Partenaires Andera Financement De Série B2 Développement ADC
BRIEF published on 03/14/2024 at 11:15, 2 years 3 months ago Andera Partners’ Portfolio Company Tubulis Secures €128 Million in Series B2 Financing Clinical Trials Andera Partners Tubulis Series B2 Financing ADC Development
PRESS RELEASE published on 03/14/2024 at 11:10, 2 years 3 months ago Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 to accelerate the development of its ADC Pipeline Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 financing to accelerate ADC pipeline development Andera Partners Tubulis €128 Million Series B2 ADC Pipeline Biotech Financing
BRIEF published on 03/14/2024 at 09:05, 2 years 3 months ago AstraZeneca acquiert Amolyt Pharma pour un montant pouvant atteindre 1,05 milliard de dollars Acquisition Biopharmaceutique AstraZeneca Amolyt Pharma Maladies Rares
BRIEF published on 03/14/2024 at 09:05, 2 years 3 months ago AstraZeneca Acquires Amolyt Pharma for up to $1.05 Billion Acquisition Biopharmaceutical AstraZeneca Amolyt Pharma Rare Diseases
PRESS RELEASE published on 03/14/2024 at 09:00, 2 years 3 months ago Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca Amolyt Pharma, a clinical-stage biopharmaceutical company specializing in therapeutic peptides, is being acquired by AstraZeneca for $1.05 billion. The transaction is expected to close in Q3 2024 Acquisition AstraZeneca Amolyt Pharma Therapeutic Peptides Rare Endocrine Diseases
Published on 07/14/2026 at 01:45, 2 hours 44 minutes ago Arctic Fox Lithium Approved for Trading on the OTCQB Venture Market and Announces DTC Eligibility
Published on 07/14/2026 at 00:01, 4 hours 28 minutes ago Captor Capital Announces Delay in its Annual Filings
Published on 07/13/2026 at 23:10, 5 hours 19 minutes ago Galaxy Ventures Inc. Announces Director Resignation
Published on 07/13/2026 at 21:35, 6 hours 54 minutes ago ATHA Energy Announces Corporate Activities Update
Published on 07/13/2026 at 20:00, 8 hours 29 minutes ago IBC Announces Share-Based Compensation to Directors
Published on 07/13/2026 at 22:30, 5 hours 59 minutes ago Half-year 2026 Results Media and Investor Conference Call and Webcast
Published on 07/13/2026 at 21:20, 7 hours 9 minutes ago Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 21:17, 7 hours 11 minutes ago EQS-Adhoc: Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 20:48, 7 hours 41 minutes ago EQS-Adhoc: Gateway Real Estate AG: Forecast for the financial year 2026
Published on 07/13/2026 at 20:23, 8 hours 6 minutes ago EQS-Adhoc: TRATON SE: Preliminary operating result for Q2 2026 exceeds market expectations
Published on 07/13/2026 at 18:00, 10 hours 29 minutes ago CP Icade - Icade reprend 100% de la propriété de la Tour Eqho à la Défense
Published on 07/13/2026 at 18:00, 10 hours 29 minutes ago PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 18:00, 10 hours 29 minutes ago THERMADOR GROUPE : publication du chiffre d'affaires semestriel 2026
